VRTX · Vertex Pharmaceuticals Inc
United States · RS rating 86 · As of 2026-11-03
| Price | 530.76 USD |
|---|---|
| 1-day change | -4.0% |
| RS rating (overall / 1M / 3M / 12M) | 86 / 73 / 81 / 72 |
| Stage | Topping |
| Composite / Minervini / CANSLIM score | 43 / 49 / 49 |
| Industry group (rank) | Medical-Biomed/Biotech (154) |
| EPS growth Q/Q | +10.7% |
| Sales growth Q/Q | +3.7% |
| Distance from 52-week high | +5.0% |
| Market cap (USD) | $110.7B |